By Super Admin

Seeking Alpha / - 22 hours ago

North Teams with Half Baked to Boost Side-Hustling Startups

Partners publish guide to success in the extra-income world TROY, Mich., Oct. 15, 2025 /PRNewswire/ -- North, a U.S.-based leader in fintech and payment solutions, has partnered with Half Baked, a thought leader serving startups, to publish a guide filled with data and resources to help...

Seeking Alpha / - 22 hours ago

Three Crown Petroleum Announces Significant Progress in its Powder River Basin Drilling Program with Initial Production from 22,500-Foot Niobrara Horizontal Well and Expansion of Development Program

The Irvine 1NH well was recently completed and began producing on October 14th Expansion of the 2025 - 2026 drilling program announced across Johnson, Campbell, and Converse Counties with two additional wells expected to spud in November 2025 Three Crown is actively seeking reliable...

Seeking Alpha / - 22 hours ago

Somnigroup to Report Third Quarter 2025 Financial Results

DALLAS, Oct. 15, 2025 /PRNewswire/ -- Somnigroup International, Inc. (NYSE: SGI, "Company" or "Somnigroup") will release its financial results for the third quarter ended September 30, 2025, before the NYSE opening of regular trading on Thursday, November 6, 2025. The Company will hold a...

Seeking Alpha / - 22 hours ago

FRUGA Introduces Passion Fruit: A Healthful, Juicy Twist on Soda

MIAMI, Oct. 15, 2025 /PRNewswire/ -- FRUGA, the soda brand redefining refreshment with real fruit and better-for-you ingredients, is proud to unveil its newest creation: Passion Fruit. After a year and a half perfecting the recipe, FRUGA has crafted a tropical flavor that's as good for...

Seeking Alpha / - 22 hours ago

Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with insulin glargine, meeting the primary endpoint INDIANAPOLIS, Oct. 15, 2025 /PRNewswire/ --...